Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.75 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.60 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497640 | 0.90 | DPP4 (0.74) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL14350043 | 0.86 | DPP4 (1.00) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL8297594 | 0.85 | DPP4 (0.92) | DPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL3838588 | 0.84 | DPP4 (0.90) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL5496951 | 0.83 | DPP4 (0.82) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL14409616 | 0.80 | DPP4 (0.73) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL15978661 | 0.76 | DPP4 (0.64) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL15978617 | 0.76 | DPP4 (0.64) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL725863 | 0.75 | DPP4 (1.00) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL5491159 | 0.75 | DPP4 (1.00) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307164-B2 | β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-7307164-B2 | β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1490335-B1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20050107390-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107390-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.